# PRDM2

Source: https://onco.cc/targets/prdm2/  
OnCo record `prdm2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Neuroblastoma and 1 more.

## Summary

S-adenosyl-L-methionine-dependent histone methyltransferase that specifically methylates 'Lys-9' of histone H3. May function as a DNA-binding transcription factor. Binds to the macrophage-specific TPA-responsive element (MTE) of the HMOX1 (heme oxygenase 1) gene and may act as a transcriptional activator of this gene.

IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Hepatocellular Carcinoma, Neuroblastoma, Papillary Renal Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: PR/SET domain 2; PR domain zinc finger protein 2; RIZ1; RIZ2; KMT8; MTB-ZF; HUMHOXY1; KMT8A
- Tags: cancer-genes-wave
- Symbol: PRDM2
- Class: transcription
- Biology: S-adenosyl-L-methionine-dependent histone methyltransferase that specifically methylates 'Lys-9' of histone H3. May function as a DNA-binding transcription factor. Binds to the macrophage-specific TPA-responsive element (MTE) of the HMOX1 (heme oxygenase 1) gene and may act as a transcriptional activator of this gene. Location: Nucleus (UniProt). Locus 1p36.21 (HGNC).
- Where found: Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC); Neuroblastoma: IntOGen driver in 1 cohort (NBL); Papillary renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9347: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9347
- UniProt Q13029: https://www.uniprot.org/uniprotkb/Q13029/entry
- NCBI Gene 7799: https://www.ncbi.nlm.nih.gov/gene/7799
- Ensembl ENSG00000116731: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116731

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Papillary renal cell carcinoma](https://onco.cc/cancers/papillary-rcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/prdm2.json